Immunological responses in women with human Papillomavirus Type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination

Smyth, LJC; Van Poelgeest, MI; Davidson, EJ; Kwappenberg, KM; Burt, DJ; Sehr, P; Pawlita, M; Man, S; Hickling, JK; Fiander, AN; Tristram, A; Kitchener, HC; Offringa, R; Stern, PL; Van Der Burg, SH

doi:10.1158/1078-0432.CCR-03-0703

All Outputs (2)

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7) (2004)
Journal Article
Davidson, E., Faulkner, R., Sehr, P., Pawlita, M., Smyth, L., Burt, D., …Stern, P. (2004). Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine, 22(21-22), 2722-2729. https://doi.org/10.1016/j.vaccine.2004.01.049

Heterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy... Read More about Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).

Immunological responses in women with human Papillomavirus Type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination (2004)
Journal Article
Smyth, L., Van Poelgeest, M., Davidson, E., Kwappenberg, K., Burt, D., Sehr, P., …Van Der Burg, S. (2004). Immunological responses in women with human Papillomavirus Type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clinical Cancer Research, 10(9), 2954. https://doi.org/10.1158/1078-0432.CCR-03-0703

Purpose: The purpose is to study the immunogenicity of heterologous prime-boost human papillomavirus (HPV) oncogene vaccination in patients with anogenital intraepithelial neoplasia (AGIN).

Experimental Design: Twenty-nine women with high-grade AG... Read More about Immunological responses in women with human Papillomavirus Type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.